4-Isothiocyanato-2-(Trifluoromethyl) benzonitrile CAS 143782-23-4 Enzalutamide Intermedia Puritas >98.0% (GC)

Description:

4-Isothiocyanato-2-(Trifluoromethyl) benzonitrile

CAS: 143782-23-4

Puritas: >98.0% (GC)

Aspectus: Off-Pulvis alba

Medium Enzalutamidis (CAS: 915087-33-1)

Contactus: Dr

Mobile/Wechat/Whatsapp: +86-15026746401

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

143782-23-4 - Descriptio:

Shanghai Ruifu Chemical Co., Ltd. est primarius fabrica 4-Isothiocyanato-2-(Trifluoromethyl)benzonitrilis (CAS: 143782-23-4) cum qualitate media Enzalutamide (CAS: 915087-33-1).Ruifu Chemical traditio totius terrarum, quantitatis competitive pretium, optimum servitium, parvas et moles in promptu habere potest.Purchase Enzalutamide Intermedia,Please contact: alvin@ruifuchem.com

143782-23-4 - Chemical Properties:

Nomen chemicum 4-Isothiocyanato-2-(Trifluoromethyl) benzonitrile
Synonyma 4-Cyano-3-(Trifluoromethyl) phenyl Isothiocyanate;Isothiocyanicum Acidum 4-Cyano-3-(Trifluoromethyl) phenyl Ester;4-Isothiocyanato-2-Trifluoromethylbenzonitrile;3-Fluoro-4-Methylphenylisothiocyanate
Stock Status In Stock, Commercial Productio
CAS Number 143782-23-4
Formulae hypotheticae C9H3F3N2S
M. Pondus 228.19 g/mol
Liquescens punctum 39.0 ad 43.0℃
Ferveret 331℃
Mico punctum 154℃
Density 1.31
Sensitiva umor sensitivus, calor sensitivus
COA & MSDS Praesto
Sample Praesto
Origin Shanghai, China
Brand Ruifu Chemical

143782-23-4 - Formularium:

Items Specifications Proventus
Aspectus Off-Pulvis alba Off-Pulvis alba
Liquescens punctum 39.0 ad 43.0℃ 41.2℃
Damnum in Siccatio <0.50% 0.19%
Puritas / Analysis Methodus >98.0% (HPLC) 98.8%
Infrared Imaginis Congruunt Structure Obsequitur
1H NMR Imaginum Congruunt Structure Obsequitur
conclusio Productum probatum est et cum datis specificationibus obsequitur
Applicationem Medium Enzalutamidis (CAS: 915087-33-1)

Sarcina / at /naviportans:

Sarcina:Fluorinated Utrem, aluminium ffoyle, 25kg/cardboard Drum, vel secundum exigentiam emptoris.
Repono Condition:Continentem arcte clausam et in loco frigido, sicco (2~8℃) reponunt et a cellis bene ventilatis ab substantiis incompossibilibus.A luce et humore protege.
Naviportans:Libera ad mundum ab aere, per FedEx / DHL Express.Ieiunium et certas traditiones provide.

commoda:

Satis capacitas: sufficientes facilities et technici

Professional Service: One stop acquireing service

Altera Package: Custom sarcina ac titulus praesto

Ieiunium Delivery: Si intra stirpem, tres dies partus praestatur

Supple firmum: Esse rationabile stirpe

Technical Support: Technology solution praesto

Custom Synthesis Service: Range from P. to kilos

High Quality: Constitutus ratio completa qualitas certitudinis

FAQ:

Quam mercari?Quaeso contactumDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com 

15 Years Experience?Plus quam XV annos experientiae habemus in fabricando et exportando amplis intermediis pharmaceuticis vel alchimicis pharmaceuticis amplis.

Mercatus principalis?Vendere mercatum domesticum, Americam septentrionalem, Europam, Indiam, Coream, Iaponicam, Australiam etc.

Commodi?Superior qualitas, parabilis pretium, officia professionalia et subsidia technica, ieiunium partus.

Qualitasfides?Qualitas strictioris temperantiae ratio.Pro instrumento analysi professionali includuntur NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Claritas, Solubilitas, Microbialis limes test, etc.

Exempla?Pleraque producta praebent exempla gratuita pro qualitate aestimationis, sumptus naviculas a clientibus solvendos.

Factory Audit?Factory audit gratissimum.Quaeso ante constitutum.

MOQ?Nec MOQ.Parvus ordo placet.

Tempus adferendi? Si intus prosapia, tres dies partus praestatur.

Transportatio?Per Express (FedEx, DHL), ab Air, per Mare.

Documenta?Post servitium venditionis: COA, MOA, ROS, MSDS, etc. praeberi possunt.

Consuetudo Synthesis?Consuetudo synthesis officia praebere potest ad optimas investigationes tuas necessitates aptandas.

Pensio conditio?Proforma cautionis primum post confirmationem ordinis mittetur, informationes nostrae ripae inclusas.Payment by T/T (Telex Transfer), PayPal, Western Union, etc.

143782-23-4 - Hazard Statements:

H302 + H312 + H312 : Noxia absorpta, in contactum cutem vel haustum.
H315: Irritatio cutis causat.
H319: Gravis oculorum irritatio.
H335: irritatio respiratorii faciam.

143782-23-4:

P501: Disponere contentorum/ continens ad probatam dispositionem plantam vastitatem.
P261: Fuge respirationem pulveris/ fumum/ gas/ caliginem/ vaporum/ imbrem.
P270: Non comedat, bibat vel fumum cum hoc utens facto.
P271 : Utere tantum foris vel in area bene ventilata.
P264: lava cutis penitus post tractantem.
P280: gere caestus tutela/vestimentum tutela/oculi praesidium/faciem tutelam.
P337 + P313: Si oculus irritatio persistit: Accipe consilium medicinae / attentio.
P305 + P351 + P338: SI IN OCULIS: caute stupam cum aqua per aliquot minutas.Lentes contactum remove, si praesens et facile factu est.Perge lotis.
P332 + P313: Si cutis irritatio fit: consilium medicinae habe / operam.
P362: tolle contaminatam vestem et lava ante reuse.
P301 + P312 + P330: SI absorptum est: voca venenum centrum/medicum si minus valere sentis.Ore eluo.
P302 + P352 + P312: SI IN CUTIS: Lava copia aquae. Voca venenum centrum/medicum si minus valere sentis.
P304 + P340 + P312 : HADRATUS : Aufer hominem ad recens aerem et serva consolatoria spirandi.Voca venenum centrum/medicum si minus valere sentis.
P403 + P233 : Repone in loco bene ventilato.Continens arcte occlusum custodi.
P405: Recipe inclusum.

143782-23-4 - Applicatio:

4-Isothiocyanato-2-(Trifluoromethyl) benzonitrile (CAS: 143782-23-4) adhibetur ut medium Enzalutamidis (CAS: 915087-33-1).Enzalutamide (XTANDI) est receptator antagonista oralis androgenia, quae probatur ab investigationis clinica et US FDA (Cibus et medicamentis Administrationis), ad progressionem metastaticae castrationis post chemotherapy tolerantia curatio cancer prostatae (id est aegris cum cancer prostatae Post chemotherapy, cancer vel cancer cellae adhuc in talibus aegris crescunt), salvos aegros proferre possunt.Mense Augusto MMXII, US FDA enzalutamide approbavit ad tractationem metastaticae castrationis-cancri prostati resistentis (mCRPC) in aegris qui antea tractati sunt.Docetaxel.

Epistulam tuam hic scribe et mitte nobis